Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Obama Alzheimer's 'roadmap' targets Genentech drug for 'landmark' prevention study

This article was originally published in Scrip

Executive Summary

Researchers in the Alzheimer's disease community should quickly familiarize themselves with an experimental drug from US Roche unit Genentech called crenezumab, National Institutes of Health (NIH) Director Dr Francis Collins declared on 15 May, in revealing a new public-private study collaboration between the US government, the South San Francisco-based company and the Arizona nonprofit Banner Alzheimer's Institute.



Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst